Related Experiment Video
Updated: Jul 12, 2025
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Thiamet G as a Potential Treatment for Polycystic Kidney Disease
Wen-Cheng Su1, Chi-Feng Hung2, Yi-Chieh Wang3
1Department of Medical Laboratory Science and Biotechnology, Yuan Pei University of Medical Technology, Hsinchu, Taiwan, R.O.C.
Insights
O-GlcNAcylation is downregulated in polycystic kidney disease (PKD) and impacts polycystic kidney disease 1 (PC1) stability. Inhibiting O-GlcNAcase with thiamet G reduced cyst formation in PKD mice, suggesting O-GlcNAcylation as a therapeutic target.
Area of Science:
- Biochemistry
- Genetics
- Nephrology
Background:
- Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder caused by Pkd1 mutations, leading to kidney cysts and renal failure.
- No current preventive treatments exist for ADPKD.
- P பாதிக்கிறது1 (PC1) mutations are responsible for most ADPKD cases.
Purpose of the Study:
- Investigate the role of O-GlcNAcylation in polycystic kidney disease (PKD) progression.
- Examine the effects of O-GlcNAcase (OGA) inhibition on PKD models.
Main Methods:
- Utilized Pkd1-knockdown mice and cells to study O-GlcNAcylation.
- Administered thiamet G, an OGA inhibitor, to PKD mice.
Main Results:
- O-GlcNAcylation and O-GlcNAc transferase (OGT) were decreased in Pkd1-silenced mouse kidneys.
- O-GlcNAcylation influences the stability and function of PC1's C-terminal cytoplasmic tail (CTT).
- Thiamet G treatment reduced renal cyst formation in PKD mice.
Conclusions:
- O-GlcNAcylation plays a distinct role in PKD cyst development.
- O-GlcNAcylation presents a potential therapeutic target for treating PKD.
Background/Aim:
Autosomal dominant polycystic kidney disease (ADPKD) is a prevalent genetic disorder primarily caused by mutations in Pkd1 (PC1), which account for the majority of ADPKD cases. These mutations contribute to the formation of cysts in the kidneys and other organs, ultimately leading to renal failure. Unfortunately, there are currently no available preventive treatments for this disease.
Materials And Methods:
In this study, we utilized Pkd1-knockdown mice and cells to investigate the potential involvement of O-GlcNAcylation in the progression of PKD. Additionally, we examined the effects of thiamet G, an inhibitor of O-GlcNAcase (OGA), on PKD mice.
Results:
Our findings indicate that both O-GlcNAcylation and OGT (O-GlcNAc transferase) were downregulated in the renal tissues of Pkd1-silenced mice. Furthermore, O-GlcNAcylation was shown to regulate the stability and function of the C-terminal cytoplasmic tail (CTT) of PC1. Treatment of PKD mice with thiamet G resulted in a reduction of renal cytogenesis in these animals.
Conclusion:
These results highlight the unique role of O-GlcNAcylation in the development of cyst formation in PKD and propose it as a potential therapeutic target for the treatment of PKD.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
08:46Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:25Chronic Kidney Disease I: Introduction
01:20Acute Kidney Injury V: Interprofessional Care
01:30Urinary Tract Calculi III: Medical Management